文献速递临床免疫分子诊断临床微生物

超敏SARS-CoV-2抗原检测在2022年上海疫情高峰期间合并症COVID-19患者管理中的应用

Application of ultrasensitive assay for SARS-CoV-2 antigen in nasopharynx in the management of COVID-19 patients with comorbidities during the peak of 2022 Shanghai epidemics in a tertiary hospital.
PubMed 文献 · Clin Chem Lab Med · 2022-12-09

本研究评估了超敏MAGLUMI® SARS-CoV-2抗原化学发光免疫分析法(MAG-CLIA)在合并症COVID-19患者中的诊断和传染性监测性能。对232例RT-qPCR阳性住院患者和477例健康供者的鼻咽拭子分析显示,以0.64 ng/L为阈值,MAG-CLIA灵敏度95.7%、特异性98.3%,优于Wondfo侧向流试验;纵向监测14例合并症患者发现8.82 ng/L抗原临界值可评估传染性。

要点

  • MAG-CLIA以0.64 ng/L为阈值诊断COVID-19,灵敏度95.7%、特异性98.3%。
  • 对Ct值35-40样本,MAG-CLIA灵敏度仍达91.46%。
  • 8.82 ng/L抗原临界值可用于评估合并症康复期患者传染性。

核心结论

  • MAG-CLIA SARS-CoV-2抗原检测是快速诊断的有效替代方法,并能评估合并症住院康复期患者的传染性。

研究设计与样本

  • 评估MAG-CLIA的分析性能(精密度、定量限、线性、特异性)。
  • 纳入232例SARS-CoV-2 RT-qPCR阳性住院患者和477例健康供者的鼻咽拭子标本。
  • 对14例COVID-19合并症患者进行长达22天的纵向监测,同时检测抗原浓度和RT-qPCR结果。
  • 以参考循环阈值(Ct)35评估确定病毒传染性的临界抗原浓度。

主要发现

  • 以0.64 ng/L为最优阈值,MAG-CLIA诊断COVID-19的灵敏度为95.7%(95% CI: 92.2-97.9%),特异性为98.3%(95% CI: 96.7-99.3%)。
  • Wondfo侧向流试验的灵敏度为34.9%(95% CI: 28.8-41.4%),特异性为100%(95% CI: 99.23-100%)。
  • 对Ct值在35至40之间的样本,MAG-CLIA灵敏度保持91.46%(95% CI: 83.14-95.8%)。
  • 纵向研究中MAG-CLIA与病毒载量时间序列显示密切的动态一致性。
  • 8.82 ng/L抗原临界值在评估合并症住院康复期患者传染性方面显示出足够的灵敏度和特异性。

关键数值与推荐

  • 诊断COVID-19的MAG-CLIA最优抗原阈值为0.64 ng/L。
  • 评估病毒传染性的参考Ct值为35。
  • 评估合并症住院康复期患者传染性的临界抗原值为8.82 ng/L。

临床怎么用

  • MAG-CLIA可用于合并症COVID-19患者的快速诊断,性能优于Wondfo侧向流试验。
  • 对合并症康复期患者,可监测抗原浓度以8.82 ng/L为临界值评估传染性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Various comorbidities associated with COVID-19 add up in severity of the disease and obviously prolonged the time for viral clearance. This study investigated a novel ultrasensitive MAGLUMI® SARS-CoV-2 Ag chemiluminescent immunoassay assay (MAG-CLIA) for diagnosis and monitoring the infectivity of COVID-19 patients with comorbid conditions during the pandemic of 2022 Shanghai. METHODS: Analytical performances of the MAG-CLIA were evaluated, including precision, limit of quantitation, linearity and specificity. Nasopharyngeal specimens from 232 hospitalized patients who were SARS-CoV-2 RT-qPCR positive and from 477 healthy donors were included. The longitudinal studies were performed by monitoring antigen concentrations alongside with RT-qPCR results in 14 COVID-19 comorbid participants for up to 22 days. The critical antigen concentration in determining virus infectivity was evaluated at the reference cycle threshold (Ct) of 35. RESULTS: COVID-19 patients were well-identified using an optimal threshold of 0.64 ng/L antigen concentration, with sensitivity and specificity of 95.7% (95% CI: 92.2-97.9%) and 98.3% (95% CI: 96.7-99.3%), respectively, while the Wondfo LFT exhibited those of 34.9% (95% CI: 28.8-41.4%) and 100% (95% CI: 99.23-100%), respectively. The sensitivity of MAG-CLIA remained 91.46% (95% CI: 83.14-95.8%) for the samples with Ct values between 35 and 40. Close dynamic consistence was observed between MAG-CLIA and viral load time series in the longitudinal studies. The critical value of 8.82 ng/L antigen showed adequate sensitivity and specificity in evaluating the infectivity of hospitalized convalescent patients with comorbidities. CONCLUSIONS: The MAG-CLIA SARS-CoV-2 Ag detection is an effective and alternative approach for rapid diagnosis and enables us to evaluate the infectivity of hospitalized convalescent patients with comorbidities.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Wang D, Lu H, Li Y, et al. Application of ultrasensitive assay for SARS-CoV-2 antigen in nasopharynx in the management of COVID-19 patients with comorbidities during the peak of 2022 Shanghai epidemics in a tertiary hospital. Clin Chem Lab Med. 2022. PMID: 36480433. doi:10.1515/cclm-2022-0661

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。